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Common alleles contribute to schizophrenia in CNV carriers
KE Tansey1, E Rees1, DE Linden1, S Ripke2,3, KD Chambert3, JL Moran3, SA McCarroll3,4, P Holmans1, G Kirov1, J Walters1, MJ Owen1 and
MC O’Donovan1
The genetic architecture of schizophrenia is complex, involving risk alleles ranging from common alleles of weak effect to rare
alleles of large effect, the best exemplar of the latter being large copy number variants (CNVs). It is currently unknown whether
pathophysiology in those with deﬁned rare mutations overlaps with that in other individuals with the disorder who do not share
the same rare mutation. Under an extreme heterogeneity model, carriers of speciﬁc high-penetrance mutations form distinct
subgroups. In contrast, under a polygenic threshold model, high-penetrance rare allele carriers possess many risk factors, of which
the rare allele is the only one, albeit an important, factor. Under the latter model, cases with rare mutations can be expected to
share some common risk alleles, and therefore pathophysiological mechanisms, with cases without the same mutation. Here we
show that, compared with controls, individuals with schizophrenia who have known pathogenic CNVs carry an excess burden of
common risk alleles (P= 2.25 × 10− 17) deﬁned from a genome-wide association study largely based on individuals without known
CNVs. Our ﬁnding is not consistent with an extreme heterogeneity model for CNV carriers, but does offer support for the polygenic
threshold model of schizophrenia. That this is so provides support for the notion that studies aiming to model the effects of rare
variation may uncover pathophysiological mechanisms of relevance to those with the disorder more widely.
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INTRODUCTION
Genetic risk for schizophrenia arises from alleles across the entire
frequency spectrum.1–5 With respect to common alleles, a recent
genome-wide association study (GWAS) reported 108 loci that
inﬂuence risk for schizophrenia; although each locus contributes
only a small effect on risk (typical odds ratios (ORs) o1.1), it has
been estimated that, ultimately, between a third and a half of the
genetic risk can be attributed to common alleles.1,6–8 Recent
exome-wide sequencing studies have also conﬁrmed a role in
schizophrenia for rare single-nucleotide variants,2,3 although, to
date, the only speciﬁc rare variants that have been robustly
implicated in the disorder are of the mutation class known as copy
number variants (CNVs).
CNVs are large, but submicroscopic, chromosomal insertions
and deletions. Currently, around 11 recurrent CNVs have been
convincingly associated with schizophrenia.4,5,9–13 Unlike common
alleles, CNVs, at least those that have been identiﬁed, confer large
effects on risk (OR ranging from about 2 to 60).4,5,9–13 Never-
theless, they are not completely penetrant,14,15 that is, they are
not sufﬁcient to cause schizophrenia. They also lack diagnostic
speciﬁcity as the same CNVs are known to inﬂuence the risk for
several neuropsychiatric disorders, including intellectual disability,
autism spectrum disorders and attention-deﬁcit hyperactivity
disorder, as well as disorders in other systems, including
cardiovascular, renal, immune and musculoskeletal.10,14,16
Competing hypotheses have been proposed about the genetic
architecture and inﬂuence of CNVs, as well as other types of rare
mutations, on schizophrenia. At the one end of the spectrum, an
extreme heterogeneity model proposes that schizophrenia
represents a highly disparate set of distinct disorders, among
which those with a speciﬁc mutation form homogeneous but
small subgroups. This model, also known as a multiple rare variant
model,17 is no longer generally sustainable given the success in
identifying common risk variants, but it may apply to the subset of
cases carrying rare high-penetrance mutations such as CNVs. That
all known CNVs have incomplete penetrance for schizophrenia
suggests that even under this model, their clinical effects depend
on other risk factors, genetic and/or environmental.15,18 If the
hypothesis of extreme heterogeneity extends from distinct alleles
to distinct pathophysiology, these additional risk factors should
not overlap between carriers of different CNVs, or between carriers
of CNVs and people with schizophrenia who do not carry CNVs.
Examples of additional CNV-speciﬁc risk factors that have been
considered include, for example, a ‘second-hit’ somatic or germ-
line mutation occurring at a gene within the CNV region but on
the unaffected chromosome, a second hit mutation elsewhere in
the genome, or mutation-speciﬁc environmental exposures. If this
is true, the results obtained from studies that seek to model the
effects of CNVs and other types of rare mutation may be useful for
understanding pathological mechanisms of disorder in those
individuals, but tell us little about the generality of cases with a
diagnosis of schizophrenia.
At the other end of the spectrum, schizophrenia can be
considered a polygenic/multifactorial disorder where disorder is
the result of an accumulation of risk factors sufﬁcient to surpass a
threshold of disease liability.19–23 Given the existence of a
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sufﬁciently large number of risk alleles segregating in the
population, it may be that each individual case has a unique risk
proﬁle, in some cases including a CNV or other type of rare
mutation. Nevertheless, cases will also carry risk alleles that are
shared with many others with the disorder, making the concept of
extreme heterogeneity at the pathophysiological level largely
meaningless.
Here, we test these extreme models by evaluating whether
individuals with a diagnosis of schizophrenia who carry a
schizophrenia-associated CNV also share a common risk allele
burden with those who have schizophrenia but no schizophrenia-
associated CNV. To measure the common risk allele burden, we
use the polygenic risk proﬁle score (RPS) method that has been
widely shown to be a powerful and valid tool for this purpose and
has, for example, revealed common allele burden overlaps
between schizophrenia and bipolar disorder.1,9,24 Essentially, an
individual’s RPS reﬂects the total number of independent risk
alleles (weighted by their effect sizes) carried by that individual, a
risk allele being deﬁned as one that surpasses speciﬁed thresholds
of signiﬁcance (PT) for disease association in an independent
GWAS study (that is, one that does not contain that individual). In
the present study, we deﬁne schizophrenia susceptibility alleles
using the largest published GWAS of schizophrenia.1 Under the
polygenic liability threshold model, but not the heterogeneity
model, we predict that CNV carriers with schizophrenia will have
an increased burden (RPS) of the common risk alleles deﬁned from
the wider population of people with schizophrenia.
MATERIALS AND METHODS
Samples
The CLOZUK schizophrenia sample used here has been described
elsewhere.1 Ascertainment of samples has been described previously.1
Brieﬂy, cases were ascertained with the assistance of Novartis, the
manufacturer of a proprietary form of clozapine (Clozaril). The sample
consisted of individuals with treatment-resistant schizophrenia according
to the clozapine registration forms completed by treating psychiatrists. The
controls were from Wellcome Trust Case Control Consortium 2 (http://
www.wtccc.org.uk/info/access_to_data_samples.html). Additional 900
controls were recruited from the UK National Blood Transfusion Service by
Cardiff University. CLOZUK samples used in this analysis include only those
individuals who passed both genome-wide association quality control and
CNV quality control resulting in a sample of 6005 controls and 5423 cases.
The UK Multicentre Research Ethics Committee approved the study and all
control samples were from participants who provided informed consent.
Although the CLOZUK is a clinical rather than a research-diagnosed
sample, we24 and subsequently the Psychiatric Genomics Consortium1
have shown that the sample is valid for genetic studies of the disorder.
Speciﬁcally of relevance to the present study, the CLOZUK sample is
indistinguishable from other samples obtained using research diagnoses
with respect to common genetic risk factors1,24 and to the rate of
occurrence or speciﬁc type of CNVs.5
Genome-wide genotype data
Samples were genotyped using the Illumina HumanOmniExpress-12v1,
HumanOmniExpressExome 8v1 and Human 1.2M Duo custom BeadChips
v1 (Illumina Inc., San Diego, CA, USA). As part of the Schizophrenia Working
Group of the Psychiatric Genomics Consortium (PGC-SCZ) analytic
pipeline,1 samples underwent routine quality control using PLINK25 and
were imputed using the prephasing/imputation stepwise approach
implemented in IMPUTE2/SHAPEIT26,27 and 1000Genomes (August 2012,
release 'v3.macGT1') as the reference data set. Only SNPs with high
conﬁdence (imputation information score40.9) were used in this analysis.
CNV calling
CNVs were called using PennCNV28 following standard protocols and
adjusting for GC content. Samples were excluded if for any one of the
following standard quality control statistics they constituted an outlier: log
R ratio standard deviation, B-allele frequency drift, wave factor and total
number of CNVs. Quality control for CNVs included joining CNVs called in
the same individual if the distance separating them was less than 50% of
their combined length. The resulting CNVs were then excluded if they
were o10 kb in size, covered by o10 probes or covered by o1 probe
per 20 kb. PLINK25 was used to exclude CNVs that overlapped low copy
repeats by more than 50% of their length or had a sample frequency of
41%. This study examined 11 speciﬁc CNVs robustly associated with
schizophrenia (Po4.1 × 10− 4) in the largest assessment to date of CNVs
previously implicated in schizophrenia (Supplementary Table 1).5 Of the
complete sample passing quality control for both CNV and SNP analysis,
145 cases and 33 controls had a schizophrenia-associated CNV.
Polygenic RPS analyses
The RPS methodology follows the procedure that has been widely adopted
since its ﬁrst description by the International Schizophrenia Consortium.29
We used a training data set as provided by the Schizophrenia Working
Group of the Psychiatric Genetics Consortium to identify the set of score
alleles from which we derived RPS for each member of the (test) CLOZUK
and control samples. The training set, as conﬁrmed by analysis of
individual genotype data by the PGC, contains no overlap with the test
data set. For those seeking to replicate the ﬁndings in samples
independent of the PGC, note the full set of SNPs required for RPS is
available at https://www.med.unc.edu/pgc/downloads. Using the ‘score’
command in PLINK,25 scores were calculated by summing the number of
susceptibility alleles of each SNP weighted by the logarithm of the SNP OR.
We used 10 progressive P-value thresholds (PT) to identify score alleles
(PTo1× 10− 8, 1 × 10− 6, 1 × 10− 4, 1 × 10− 3, 0.01, 0.05, 0.1, 0.2, 0.5, 1).
Logistic regressions tested whether the resulting RPS was associated with
phenotype status.
Under the polygenic liability threshold model, the key prediction is that
cases with a schizophrenia-associated CNV would have a higher RPS than
controls. To test this, we contrasted RPS in the following tests (see also the
section on power below):
(1) Schizophrenia cases without a schizophrenia-associated CNV vs
controls. This test is a positive control for the ability of RPS to predict
affected status generally in our sample.
(2) Schizophrenia cases with a schizophrenia-associated CNV vs controls.
This is the key test of the primary hypothesis.
(3) Schizophrenia cases with a schizophrenia-associated CNV vs controls
with a schizophrenia-associated CNV. This is an additional (though
less-well-powered) test of the primary hypothesis.
Given the above primary tests supported the polygenic liability
threshold model, we undertook a number of secondary tests. We
postulated that people carrying CNVs would require a lower burden of
common alleles to become affected than those without a CNV; that within
cases who are CNV carriers, those with large effect CNVs (deﬁned here as
above the median OR, that is,47) would have lower RPS than those with
CNVs with lower effect sizes, but that each subgroup would still have
higher RPS than controls. Effect sizes for CNVs were taken from Rees et al.5
To test the above we contrasted RPS in:
(1) Schizophrenia cases with a schizophrenia-associated CNV vs schizo-
phrenia cases without a schizophrenia-associated CNV;
(2) Schizophrenia cases with a schizophrenia-associated CNV with an OR
greater than 7 vs schizophrenia cases with a schizophrenia-associated
CNV with an OR less than 7;
(3) Schizophrenia cases with a schizophrenia-associated CNV with an OR
greater than 7 vs controls without a schizophrenia-associated CNV;
(4) Schizophrenia cases with a schizophrenia-associated CNV with an OR
less than 7 vs controls without a schizophrenia-associated CNV; and
(5) Ordinal logistic regression by CNV OR, which tests for a relationship
between RPS and ranked ORs of the CNVs.
The within-case tests are more limited in power (see the section on
power).
Each analysis included six population covariates. We calculated the
proportion of variance explained (Nagelkerke’s R2) by subtraction of a full
model (covariates+RPS) score from a reduced model (covariates only).
Polygenic scores analysis power calculation
We performed power calculations for RPS using the methodology and R
script available from Dudbridge.30 The calculation takes into account
CNVs, polygenic risk and schizophrenia
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factors including discovery and training sample size, number of SNPs used,
case− control ratio and proportion of total variance that is explained by
common genetic effects (h2SNP) in both the discovery and training data sets.
The PGC-SCZ sample size without CLOZUK was 67 992, with a sampling
proportion of cases of 0.422. The CLOZUK set of cases without a
pathogenic CNV plus all controls was 11 283 with a sampling proportion
of cases of 0.468. Life-time risk for schizophrenia was set to 0.01,31 with the
proportion of total variance that is explained by common genetic effects
(h2SNP) set to 0.25 (ref. 7); 96 874 SNPs were used for PT o0.5, the threshold
we use to illustrate the power calculation.
We calculated the value of h2SNP for which we had 80% power. For the
analysis of schizophrenia cases with a schizophrenia-associated CNV vs
controls, the sample size restricted to cases with a pathogenic CNV plus all
controls was 6148, with a sampling proportion of cases of 0.023.
Prevalence of individuals with schizophrenia carrying a known pathogenic
CNV was set to 2.70× 10− 4 (rate in the general population of people with
schizophrenia with one of the known pathogenic CNVs). For the analysis of
schizophrenia cases with a schizophrenia-associated CNV vs controls with a
schizophrenia-associated CNV, the CLOZUK sample size of CNV carriers was
178, with a sampling proportion of cases with a pathogenic CNV to
controls with a pathogenic CNV of 0.78, and the prevalence of
schizophrenia among individuals carrying a known pathogenic CNV being
set to 0.0651.14 For schizophrenia cases with a schizophrenia-associated
CNV vs schizophrenia cases without a schizophrenia-associated CNV,
CLOZUK sample size was 5423 with a sampling proportion of cases with
and without a pathogenic CNV of 0.027.
RESULTS
Polygenic RPS analyses
Schizophrenia cases without a schizophrenia-associated CNV had
a signiﬁcantly higher RPS for schizophrenia compared with
controls (PT = 0.05, R
2 = 0.109, P= 1.43 × 10− 287; Figure 1). In the
tests of the primary hypothesis, cases with a schizophrenia-
associated CNV had a signiﬁcantly higher RPS than controls
(PT = 0.05, R
2 = 0.056, P= 2.25 × 10− 17); indeed, even among the
small number of CNV carriers, RPS signiﬁcantly distinguished
between those with and without schizophrenia (PT = 0.05,
R2 = 0.089, P= 3.58 × 10− 4), cases having a higher RPS than
controls.
Polygenic RPS analysis by CNV OR
Among the cases, schizophrenia RPS was not signiﬁcantly different
between those with and without a schizophrenia-associated CNV
(PT = 0.05, R
2o0.0001, P= 0.334); Figure 2 and Supplementary
Figures 1 and 2. We found evidence that common alleles
contribute to risk in carriers of high OR CNVs and to risk in those
with low OR CNVs (high OR vs controls; PT = 0.05, R
2 = 0.0341,
P= 1.10 × 10− 7: low OR vs controls; PT = 0.05, R
2 = 0.0708,
P= 5.99 × 10− 12) (Figure 2). As expected under a liability threshold
model, at most PT thresholds, schizophrenia cases with a high OR
(OR47) CNV had a lower RPS for schizophrenia compared both
with cases without a known schizophrenia-associated CNV and
with cases with a lower OR (ORo7) CNV (Figure 2). However, the
results were only nominally signiﬁcant at a subset of the PT values;
hence, although the trends are in the direction predicted by the
hypotheses, we do not consider these secondary tests as robust.
We found no consistent evidence for a difference in RPS between
schizophrenia cases with a low OR (ORo7) CNV compared with
cases without a schizophrenia-associated CNV.
Polygenic RPS analysis power calculation
We had complete power to detect an RPS difference between
cases without CNVs and controls. We had 80% power to detect an
RPS difference between cases with a schizophrenia-associated
CNV vs controls even if the h2SNP (proportion of total phenotypic
variance that is explained by common genetic effects) for
schizophrenia in CNV carriers is as low as 0.0175. In our analysis
of cases with a schizophrenia-associated CNV vs controls with a
schizophrenia-associated CNV, we had 80% power to detect an
RPS difference if the h2SNP for schizophrenia to CNV carriers was
0.25, the same as it is for schizophrenia in general. For the
secondary analysis, we had 80% power to detect an RPS difference
between cases with schizophrenia-associated CNV and cases
without a schizophrenia-associated CNV, even if the difference in
the contribution of h2SNP to each group was as little as 0.043. We
therefore conclude our analyses are well powered, although we
cannot exclude small reductions in the burden of common risk
Figure 1. Proportion of variance in schizophrenia in CLOZUK explained by risk proﬁle scores. R2 is Nagelkerke’s R2 obtained by subtracting the
R2 of the full model (covariates+RPS) from the R2of a reduced model (covariates only). Ten different training P-value thresholds (PT) for
selecting risk alleles are denoted by the colour of each bar (legend above plot). Two-sided P-values for evidence at Po0.05 are displayed.
For each analysis of A vs B, the ﬁrst sample was coded as 1 and the second as 0 in the logistic regression. CNV, copy number variant;
RPS, risk proﬁle score.
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alleles in cases that are CNV carriers compared with cases that
are not.
DISCUSSION
The primary goal of this study was to test the hypothesis that
within schizophrenia, individuals deﬁned by known pathogenic
mutations are completely distinct from the wider population of
people with the disorder with respect to their genetic aetiology.
Our results do not lend support to the extreme heterogeneity
hypothesis. Instead, we found that common risk alleles contribute
to the disorder in those who also carry a deﬁned relatively high-
penetrance mutation. This was also true for CNVs whose effect size
is at the larger end of the spectrum (OR47), and even the 3q29
and 22q11 deletions that have exceptional effect sizes still had
elevated burdens of common alleles (see Supplementary Figures 3
and 4), although we did not have sufﬁcient power to evaluate RPS
for individual CNVs. Since the common risk alleles are derived
from studies composed almost entirely of those without
pathogenic CNVs, this must suggest that shared risk variants
operate in those with and without a CNV. In so far as risk alleles
must ultimately reﬂect biological perturbations that result in
pathophysiological processes, it follows that those with distinct,
deﬁned rare mutations do not form subgroups with a circum-
scribed pathophysiology.
Our ﬁnding is relevant for pathophysiological models of
schizophrenia. If an extreme heterogeneity model operates
whereby despite similar symptoms, there exists a myriad of sub-
disorders deﬁned by non-overlapping aetiologies and distinct
pathophysiologies, it might also be the case that studies aiming to
model high-penetrance mutations in model systems would have
no, or very limited applicability, for the disorder more widely. We
do not interpret our ﬁndings as suggesting that schizophrenia is a
homogeneous disorder where every individual has an identical set
of risk alleles and pathophysiology. Rather, we suggest that
people with the disorder, including carriers of mutations of large
effect, have overlapping pathophysiologies and that these are not
demarcated by a single mutation. Inevitably, the degree to which
risk alleles and pathophysiological processes are shared between
pairs of individuals will vary, but that they do overlap, albeit to a
greater or lesser extent, makes it likely that mutations of large
effect will have their effects mediated by processes that are
relevant to a proportion of people with the disorder who do not
carry that mutation.
A second important observation, albeit one that almost
inevitably ﬂows from the primary observation, is that among
CNV carriers the RPS statistically differentiates between those who
do and do not develop schizophrenia. Although the variance
currently explained maximizes at around 0.1 (Figure 1), this offers
the possibility that as more of common genetic variance for
schizophrenia is captured, RPS scoring might make a contribution
to predicting the adult psychiatric phenotypic consequences of
carrying large-effect, but incompletely penetrant alleles.
As is the case for predicting affected status more widely, it
seems unlikely that RPS alone will offer sufﬁcient discriminatory
power.32 However, one might envisage that it could do so in the
future when combined with additional endophenotypes (used
here to denote heritable measures like RPS and index genetic
liability) or with measures (for example, brain imaging, childhood
cognition and psychosocial development) that do not necessarily
meet the criteria for endophenotypes (see GotteFsman and
Gould33 for full discussion) but may nevertheless index increased
risk of the disorder. A separate question that will require the
exploration of larger GWAS data sets of those disorders is whether
RPS might also be used to discriminate between different
childhood outcomes, for example being developmentally unim-
paired vs having ADHD, and/or ID, and/or ASD, or indeed some of
the other adult outcomes that are associated with one or more of
the CNVs we have investigated such as epilepsy and obesity.10
This will require the exploration of larger GWAS data sets of those
disorders, but it seems reasonable to propose that factoring in RPS
(and other risk factors) for those disorders might similarly begin to
provide predictive power.
CONCLUSIONS
Individuals with schizophrenia harbouring a schizophrenia-
associated CNV also have a signiﬁcant predisposition arising from
common risk alleles that inﬂuence risk in the wider population of
people with the disorder. Our results offer support for a polygenic
threshold model rather than an extreme heterogeneity model
of schizophrenia, even within CNV carriers. The additional
Figure 2. Proportion of variance in schizophrenia in CLOZUK explained by risk proﬁle scores by CNV OR. R2 is Nagelkerke’s R2obtained by
subtracting the R2 of the full model (covariates+RPS) from the R2 of a reduced model (covariates only). Ten different training P-value
thresholds (PT) for selecting risk alleles are denoted by the colour of each bar (legend above plot). Two-sided P-values for evidence at Po0.05
are displayed. For each analysis of A vs B, the ﬁrst sample was coded as 1 and the second as 0 in the logistic regression. R2 values above 0
symbolize that case status is associated with increased risk for schizophrenia and R2 values below 0 symbolize that case status is associated
with decreased risk for schizophrenia. CNV, copy number variant; OR, odds ratio; RPS, risk proﬁle score.
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contribution from common alleles may in part explain why some
individuals develop schizophrenia rather than another disorder
linked to the same CNV.
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